LOP 628

Drug Profile

LOP 628

Alternative Names: Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate - Novartis; Anti-c-kit humanised IgG1/κ antibody-maytansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maitansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maytansine conjugate - Novartis

Latest Information Update: 05 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Mar 2015 Novartis suspends phase I trial in Solid tumours and Acute myeloid leukaemia in the USA, Australia and Netherlands (NCT02221505)
  • 01 Dec 2014 Phase-I clinical trials in Acute myeloid leukaemia in USA, Australia and the Netherlands (IV)
  • 01 Dec 2014 Phase-I clinical trials in Solid tumours in USA, Australia and the Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top